Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • DOP directes NPPA to...

    DOP directes NPPA to refix the price of Phenobarbitone 30 mg and Sodium Valprorate 200 mg tablets

    Written by savita thakur thakur Published On 2017-02-10T10:05:53+05:30  |  Updated On 10 Feb 2017 10:05 AM IST
    DOP directes NPPA to refix the price of Phenobarbitone 30 mg and Sodium Valprorate 200 mg tablets

    The Department of Pharmaceuticals (DoP) has directed the National Pharmaceutical Pricing Authority (NPPA) to examine the data/information once again and to re-fix the retail price of Phenobarbitone 30 mg and Sodium Valprorate 200 mg tablets.


    This came after Abbott healthcare Pvt has filed a petition against the decision of NPPA to revalue the data once again, as the NPPA has fixed the prices of said drugs on the basis of August, 2015 data.


    Earlier NPPA has fixed Rs. 0.93 per tablet for Phenobarbitone 30mg tablet and Rs. 3.07 per tablet Sodium Valprorate 200mg tablet.


    During the personnel hearing, the Petitioner company contended that while fixing ceiling price of Phenobarbitone 30 mg. tablet, NPPA considered August, 2015 data while NPPA had subsequently notified upward revision of ceiling price for Phenobarbitone 30mg on 24.02.2016 Rs. 1.63 and Rs 1.59 on 02.03.2016 towards negative WPI reduction, a fact which was not considered while fixing the price .


    With regards to Sodium Valprorate, the company stated the NPPA considered the price Epilex 200 while fixing the price of Sodium Valprorate, when the fact is that the manufacturing & marketing of Epilex 200mg Tablets 15’s pack have been stopped since year 2011. Moreover, NPPA considered Epilex 200mg Tablets 10’s PTR as Rs 2.61 per tab, whereas actual PTR should be Rs. 2.71 per tab.


    In reply, NPPA has commented that the company has not submitted any representation to NPPA in this regard.


    During the Examination, the department of pharmaceuticals (DOP) looked into the company’s grievance regarding Phenobarbitone 30 mg, that NPPA took the August,2015 PTR while fixing ceiling price in June, 2016, instead of taking the revised ceiling price granted to them in February/March, 2016. The DOP then found that the contention of the petitioner company that taking August,2015 PTR and ignoring February/March, 2016 price fixation by NPPA, while fixing ceiling price in June, 2016 has got merit.


    In view of the above, the department of pharmaceuticals (DOP) has come out with a decision that;




    NPPA is hereby directed to refix the ceiling price for Phenobarbitone 30 mg. tablet using revised prices. NPPA is also directed to examine the documents submitted by the petitioner company on merit, and refix/revise the price of Sodium Valprorate, if necessary.


    Abbott healthcareDepartment of PharmaceuticalsDOPfixing pricesNational Pharmaceutical Pricing AuthorityNPPAPhenobarbitone 30 mgprice ceilingprice fixationSodium Valprorate 200 mg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok